Originally viewed as a marker, with high levels of ROR1 associated with aggressive CLL, the accumulating data related to the ROR1 in cell signaling cascades have propelled it as a new target for developing immunological therapies, like monoclonal antibodies, such as zilovertamab, and CAR T-cell therapy. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.